

**Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
and 18 U.S.C. §208 (b)(3)
Particular Matter of General Applicability Waivers**

Name: Marvin Meyer, Ph.D.

Committee: Advisory Committee for Pharmaceutical Science and Clinical Pharmacology

Meeting Date(s): July 22-23, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda items: (1) the current thinking on issues pertaining to the use of nanotechnology in drug manufacturing, drug delivery, or drug products; (2) current strategies and directions for the testing of lead in pharmaceutical products; (3) the bioequivalence methods for locally acting drugs that treat gastrointestinal (GI) conditions; (4) the use of inhaled corticosteroids dose-response as a means to establish bioequivalence of inhalation drug products; and, (5) the drug classification of orally disintegrating tablets (ODT) as a separate dosage form and the need for subsequent guidance on expectations and recommendations that would be required for applications proposing the dosage form, I am eligible to receive particular matter of general applicability waivers under 712(c)(2)(B) and 18 U.S.C. §208 (b)(3).

Type of Interest	Involvement	Magnitude
Stock	Two Sector Mutual Funds	Between \$50,001 and \$100,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of the interest, the waivers are not valid.

_____/s/_____
Signature

_____6/6/08_____
Date